Mitomycin C.
In conclusion, recent work has highlighted the fact that NSCLCs have elevated levels of NQO1 activity and that such an increase represents an excellent target for therapeutic exploitation. The 5-year survival rate seen with lung cancer is dismal and there is a high number of cancer deaths associated with this disease each year. This renders the design of molecules that can be activated by NQO1 (such as MeDZQ or CB 10-200) an extremely important and urgent issue.
Gibson
N W
NW
Cancer Research Group, Central Research Pfizer Inc., Groton, CT.
Ross
D
D
D002289:Carcinoma, Non-Small-Cell Lung / Q000201:enzymology*; D015195:Drug Design; D006801:Humans; D008175:Lung Neoplasms / Q000201:enzymology*; D016685:Mitomycin / Q000378:metabolism*; D016660:NAD(P)H Dehydrogenase (Quinone) / Q000378:metabolism*; D010084:Oxidation-Reduction; D011809:Quinones / Q000378:metabolism; D013379:Substrate Specificity
D011809:Quinones; D016685:Mitomycin; D016660:NAD(P)H Dehydrogenase (Quinone)